Advanced analytical technologies now offer the detailed assessments biopharma drug developers need.

What do companies need to consider when developing next-gen medicines for rare diseases?

This 6 episode miniseries will take listeners behind the scenes of a range of projects at the Drugs for Neglected Diseases initiative

The COVID-19 pandemic exposed weaknesses in pharma supply chains. It’s time to address these.

How can multi-column chromatography support companies as they set their sights on intensified bioprocesses?

Is commercializing gene therapy manufacturing an unsolvable problem? We ask an expert on the frontlines.

Medicare publishes policy for amyloid mAbs and Alzheimer’s disease. It’s not good news for Aduhelm.

Get excited, because the results are in! Find out who won the 2022 Innovation Awards

African vaccine production needs a boost. Here’s how Aspen is working to make that happen.

We sat down to talk shop with Novo Nordisk Executive Vice President Ludovic Helfgott